Prescribing information



Tafinlar + Mekinist is the first and only targeted treatment available for patients with BRAF V600-positive metastatic NSCLC1,2


Image of Cosentyx logo

is a proven, first-line treatment for patients with BRAF+ V600 mutation3

Find out more

Image of Cosentyx logo

has a well established safety

Find out more


offers convenient oral dosing1,2

Find out more


  1. Tafinlar (dabrafenib) Summary of Product Characteristics
  2. Mekinist (trametinib) Summary of Product Characteristics.
  3. Planchard D, et al. Lancet Oncol 2017;18:1307–1316.
Rate this content: 
No votes yet
UK | August 2021 | 118587

Ask Speakers


Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at Adverse events should also be reported to Novartis via or online through the pharmacovigilance intake (PVI) tool at
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at